Ciara Freeman, MD, PhD, discusses anito-cel's unique functions and benefits for treating multiple myeloma.
Videos
Nini Wu, MD, MBA, discusses how community oncology practices can leverage technology to maximize efficiency and reduce administrative burdens.
Madhur Nayan, MD, PhD, discusses a new machine learning model developed to enhance prostate cancer screening.
Panelists discuss how important end points for evaluating new myelofibrosis therapies include overall survival, symptom improvement, splenic volume reduction, hematologic parameters, disease modification, safety, and patient-reported outcomes, all of which help assess the impact of treatment on both clinical outcomes and quality of life.
Panelists discuss how investigational therapies beyond Janus kinase (JAK) inhibition, including epigenetic modulation, telomerase inhibition, PI3K/AKT/mTOR pathway inhibition, immune modulation, TGF-β inhibition, and novel anti-fibrotic agents, are showing promise in improving efficacy and targeting different disease pathways in myelofibrosis.
Dong Chen, MD, PhD, discusses the obstacles and opportunities for growth in posttreatment cancer detection.
Dong Chen, MD, PhD, discusses the most recent advancements in posttreatment cancer detection.
Jack Khouri, MD, discusses data from a multicenter study of teclistamab in patients with relapsed/refractory multiple myeloma who had prior exposure to BCMA-directed therapy.
Panelists discuss how steroid dosing for chronic graft-vs-host disease (cGVHD) typically starts at 0.5-1 mg/kg/day depending on severity, with careful tapering to avoid flares.
Panelists discuss how in polycythemia vera (PV), defining and managing treatment resistance or intolerance is crucial, requiring careful monitoring and timely intervention, including assessing adherence, evaluating mutations, and making therapeutic adjustments such as dose modifications, switching to alternative therapies like ruxolitinib or interferon, and employing a multidisciplinary approach to ensure optimal disease control and patient outcomes.
Panelists discuss how patient education and multidisciplinary involvement are critical for early detection of chronic graft-vs-host disease (cGVHD).
Panelists discuss how the choice between hydroxyurea (HU) and interferon (IFN) for cytoreductive therapy in polycythemia vera (PV) depends on factors such as patient age, long-term safety, tolerability, comorbidities, response to previous treatments, and patient preferences, with HU often preferred in older patients and IFN favored for younger patients, those intolerant to HU, or those seeking potential disease-modifying effects.
Andrew Kuykendall, MD, discusses data from a phase 2 trial of fedratinib for the treatment of myeloproliferative neoplasms.
Colin P.N. Dinney, MD, provides some background on translational analyses from the BOND-003 and CORE-001 trials.
Ruben Olivares, MD, discusses the first remote transcontental HIFU therapy for prostate cancer.
Nicole A. Cipriani, explores the clinical relevance of the BRAF p.V600E mutation in papillary thyroid carcinoma and its potential role in guiding treatment decisions.
Aditya Shreenivas, MD, MS, discusses the clinical trial that led to the FDA approval of penpulimab in nasopharyngeal carcinoma.
Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs intravenous pembrolizumab, plus chemotherapy, for the treatment of metastatic NSCLC may impact patient experience and clinical workflow.
Aditya Shreenivas, MD, MS, discusses findings from the clinical trial supporting the FDA approval of penpulimab in nasopharyngeal carcinoma.
Yelena Y. Janjigian, MD, discusses how to manage the potential adverse events of pembrolizumab when using the recently approved combination of pembrolizumab plus trastuzumab and chemotherapy.
Ruben Olivares, MD, discusses the important implications of the first transcontinental robot-assisted focal therapy procedure for prostate cancer.
Amandeep Salhotra, MD, discusses data from the phase 3 Precision-T trial of Orca-T in patients with advanced hematologic malignancies.
Panelists discuss how the MOMENTUM trial demonstrated momelotinib’s superiority over danazol in symptomatic anemic myelofibrosis patients, showing significant improvements in symptoms (the primary end point), meaningful spleen volume reduction (SVR25/SVR35), and anemia benefits, with experts noting that the inclusion of a washout period provided clearer evidence of momelotinib’s efficacy profile compared to the SIMPLIFY-2 trial.
Panelists discuss how second-line treatment decisions for myelofibrosis patients failing ruxolitinib can be guided by clinical trial data such as that from SIMPLIFY-2, whereas momelotinib offers comparable spleen control with superior anemia benefits and potential symptom improvement, although experts emphasize the importance of considering a patient’s specific failure pattern and setting appropriate expectations when switching therapies.
Olalekan O Oluwole, MD, MBBS, discusses a study investigating shorter monitoring times post CAR T therapy.
Quoc-Dien Trinh, MD, MBA, discusses a sub-analysis of the phase 3 ARANOTE trial, which focused on Black patients with metastatic hormone-sensitive prostate cancer.
Amandeep Salhotra, MD, discusses Orca-T and its evaluation in the phase 3 Precision-T trial in patients with advanced hematologic malignancies.
Panelists discuss how managing myelofibrosis patients with challenging cytopenias involves careful treatment selection, regular monitoring of blood counts, and tailored dose adjustments to balance disease control with the risks of exacerbating hematologic toxicities.
Panelists discuss how selecting and optimizing Janus kinase (JAK) inhibitor therapy in myelofibrosis involves personalizing treatment based on patient risk factors, comorbidities, and preferences while emphasizing regular monitoring to manage adverse effects and improve quality of life.
